Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Akebia Therapeutics in a report released on Wednesday, June 4th. HC Wainwright analyst M. Caufield forecasts that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Akebia Therapeutics' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics' Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.02) EPS, FY2026 earnings at $0.11 EPS, FY2027 earnings at $0.19 EPS, FY2028 earnings at $0.41 EPS and FY2029 earnings at $0.52 EPS.
Other research analysts have also recently issued research reports about the stock. Piper Sandler boosted their price objective on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Wall Street Zen raised shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 3rd. Leerink Partnrs raised shares of Akebia Therapeutics to a "strong-buy" rating in a research note on Monday, April 28th. Jefferies Financial Group started coverage on shares of Akebia Therapeutics in a research note on Tuesday, April 1st. They issued a "buy" rating and a $6.00 price target on the stock. Finally, Leerink Partners started coverage on shares of Akebia Therapeutics in a research note on Monday, April 28th. They issued an "outperform" rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $6.75.
Read Our Latest Stock Report on AKBA
Akebia Therapeutics Stock Down 3.5%
Shares of Akebia Therapeutics stock traded down $0.14 during trading on Friday, reaching $3.83. 8,101,052 shares of the company were exchanged, compared to its average volume of 3,105,368. Akebia Therapeutics has a twelve month low of $0.80 and a twelve month high of $4.06. The business has a 50-day moving average price of $2.48 and a 200-day moving average price of $2.17. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -16.65 and a beta of 0.85.
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.06. The business had revenue of $57.34 million for the quarter, compared to analyst estimates of $44.88 million.
Institutional Trading of Akebia Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. bought a new stake in Akebia Therapeutics during the fourth quarter worth $26,000. PDS Planning Inc bought a new stake in Akebia Therapeutics during the fourth quarter worth $28,000. Mariner LLC bought a new stake in Akebia Therapeutics during the fourth quarter worth $28,000. Unified Investment Management raised its position in Akebia Therapeutics by 47.8% during the first quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Cibc World Markets Corp bought a new stake in Akebia Therapeutics during the fourth quarter worth $37,000. 33.92% of the stock is owned by institutional investors.
Insider Transactions at Akebia Therapeutics
In other news, CAO Richard C. Malabre sold 13,334 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $3.53, for a total value of $47,069.02. Following the sale, the chief accounting officer now owns 266,914 shares of the company's stock, valued at $942,206.42. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.00% of the stock is currently owned by insiders.
Akebia Therapeutics Company Profile
(
Get Free Report)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Read More
Before you consider Akebia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.
While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
